Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

被引：0
|
作者：
James P. Thomas
Kendra D. Tutsch
James F. Cleary
Howard H. Bailey
Rhoda Arzoomanian
Dona Alberti
Kris Simon
Chris Feierabend
Kimberly Binger
Rebecca Marnocha
Amy Dresen
George Wilding
机构：
[1] University of Wisconsin Comprehensive Cancer Center,
[2] University of Wisconsin Medical School,undefined
[3] 600 Highland Ave,undefined
[4] Madison,undefined
[5] WI 53792,undefined
[6] USA,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2002年 / 50卷
关键词：
Flavopiridol Phase I Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Abstract
引用
收藏
页码：465 / 472
页数：7
相关论文
共 50 条
  • [1] Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
    Thomas, JP
    Tutsch, KD
    Cleary, JF
    Bailey, HH
    Arzoomanian, R
    Alberti, D
    Simon, K
    Feierabend, C
    Binger, K
    Marnocha, R
    Dresen, A
    Wilding, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) : 465 - 472
  • [2] Flavopiridol, a cyclin-dependent kinase inhibitor
    Lansiaux, A
    Bailly, C
    BULLETIN DU CANCER, 2000, 87 (10) : 697 - 701
  • [3] Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol
    Shapiro, GI
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4270S - 4275S
  • [4] Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
    Zhai, SP
    Senderowicz, AM
    Sausville, EA
    Figg, WD
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (05) : 905 - 911
  • [5] Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
    Senderowicz, AM
    Headlee, D
    Stinson, SF
    Lush, RM
    Kalil, N
    Villalba, L
    Hill, K
    Steinberg, SM
    Figg, WD
    Tompkins, A
    Arbuck, SG
    Sausville, EA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 2986 - 2999
  • [6] Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Tan, AR
    Yang, XW
    Berman, A
    Zhai, SP
    Sparreboom, A
    Parr, AL
    Chow, C
    Brahim, JS
    Steinberg, SM
    Figg, WD
    Swain, SM
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5038 - 5047
  • [7] Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials
    Senderowicz, AM
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) : 313 - 320
  • [8] Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
    Adrian M. Senderowicz
    Investigational New Drugs, 1999, 17 : 313 - 320
  • [9] A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Dickson, Mark A.
    Shah, Manish A.
    Rathkopf, Dana
    Tse, Archie
    Carvajal, Richard D.
    Wu, Nian
    Lefkowitz, Robert A.
    Gonen, Mithat
    Cane, Lauren M.
    Dials, Heather J.
    Schwartz, Gary K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1113 - 1121
  • [10] A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Mark A. Dickson
    Manish A. Shah
    Dana Rathkopf
    Archie Tse
    Richard D. Carvajal
    Nian Wu
    Robert A. Lefkowitz
    Mithat Gonen
    Lauren M. Cane
    Heather J. Dials
    Gary K. Schwartz
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1113 - 1121
12345